RxDoctor Payments Data

Christine Gerula, MD

Cardiovascular Disease · Newark, NJNPI 1619908878

Payments from drug & device makers

$1,846in general payments, 2019–2025

Across 19 payments — averaging $97.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$625
  • Boehringer Ingelheim$250
  • Amgen$243
  • Shockwave Medical, Inc$171
  • Novo Nordisk$125
  • AstraZeneca$116
  • plus $315 from 4 others

What the payments were for

  • Food & beverage$1,78597%
  • Education$613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,846 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$100,690
Medicare patients
1,257
Services billed
2,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan279$302,058
VyndamaxTafamidis12$264,528
EliquisApixaban167$175,139
JardianceEmpagliflozin149$172,428
FarxigaDapagliflozin Propanediol38$42,966
BrilintaTicagrelor26$17,552
VascepaIcosapent Ethyl32$16,521
Icosapent Ethyl19$6,570
Repatha SureclickEvolocumab11$6,054
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine27$5,224
Atorvastatin Calcium480$4,162
Rosuvastatin Calcium171$3,320
Ezetimibe179$2,990
Metoprolol Succinate225$2,958
Carvedilol384$2,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$94$439,667179 claims
Boehringer IngelheimJardiance$250$172,428149 claims
AstraZenecaFarxiga, Brilinta$116$60,51864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →